ClinicalTrials.gg
CompletedNCT00482079Updated Mar 28, 2017

A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

A Phase 2 interventional study of MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks and Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks in Diabetes Mellitus, Type II, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-03-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 years after the study started (first participant enrolled May 2003, registered Jun 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
743
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Merck & Co., Inc.

Enrollment
21st of 170
743 · median 192
Started
2003
with 7 others
Phase 2
21 of 181
none open now
Registered
24th of 181
by date

Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 21st largest by enrollment of the 170 interventional ones that give a count, is one of 8 that started in 2003, is one of 21 in phase 2, and was the 24th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc as a file.
02

Study summary

A dose-ranging study of MK0431 in patients with type 2 diabetes who have inadequate control of their blood sugar.

03

Conditions studied

  • Diabetes Mellitus, Type II
04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 21 to 70, You are a man or non-pregnant woman

Exclusion criteria

Exclusion Criteria:

  • Have a history of type I diabetes
  • You are on a weight loss program with ongoing weight loss or taking weight loss medications
  • You have a history of minor surgery
  • You have received drugs within 8 weeks of study start
  • You have or C
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
743 participants (actual)

Interventions

  • DrugMK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks
  • DrugComparator: placebo (unspecified) / Duration of Treatment: 21 Weeks
06

What researchers measure

Primary outcomes

  1. To asses the effectiveness of MK0431 compared to placebo

    Time frame: over 12 weeks

Secondary outcomes

  1. To test the safety and tolerability of MK0431 in patients with type 2 diabetes

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007 Jan;61(1):171-80. doi: 10.1111/j.1742-1241.2006.01246.x. Epub 2006 Dec 5. PubMed 17156104 ↗
  • Ommen ES, Xu L, O'Neill EA, Goldstein BJ, Kaufman KD, Engel SS. Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Ther. 2015 Mar;6(1):29-40. doi: 10.1007/s13300-015-0098-y. Epub 2015 Jan 30. Erratum In: Diabetes Ther. 2015 Mar;6(1):97-8. doi: 10.1007/s13300-015-0101-7. PubMed 25633134 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2003 to primary completion in Aug 2004, 15 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 15 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2007
First posted
Jun 4, 2007
StartActual
May 13, 2003
Primary completionActual
Aug 25, 2004
CompletionActual
Jun 15, 2006
Last update
Mar 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00482079
Responsible party
Sponsor
First posted
Jun 4, 2007
Start date
May 13, 2003
Primary completion
Aug 25, 2004
Completion
Jun 15, 2006
Last update
Mar 28, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion